Results 21 to 30 of about 33,250 (191)
Numerous studies have documented ultrastructural abnormalities in malignant megakaryocytes from bone marrow (BM) of myelofibrosis patients but the morphology of these cells in spleen, an important extramedullary site in this disease, was not investigated
Maria Zingariello +8 more
doaj +1 more source
JAK2V617F mutation in a patient with B-cell chronic lymphocytic leukemia and prefibrotic primary myelofibrosis [PDF]
Introduction. Secondary malignancies, particularly solid tumors, are common in patients with chronic lymphocytic leukemia (CLL), but association of myeloproliferative neoplasms and chronic lymphocytic leukemia in the same patient is very rare ...
Ristić Slobodan +5 more
doaj +1 more source
The JAK2 gene encodes for a non‐receptor tyrosine kinase that plays a key role in the JAK/STAT signaling transfer pathway. Genetic polymorphisms of this gene have been indicated to be associated with myeloproliferative neoplasm‐associated thrombosis in ...
Nguyen Thy Ngoc +3 more
doaj +1 more source
Epigenetics in myeloproliferative neoplasms
The myeloproliferative neoplasms (MPNs) are a group of acquired clonal disorders where mutations drive proliferative disease resulting in increased blood counts and in some cases end-stage myelofibrosis.
Graeme Greenfield, Mary Frances McMullin
doaj +1 more source
Brief update on systemic therapies in myeloproliferative neoplasms [PDF]
Janine Steichen, Dominik Wolf
openalex +1 more source
Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
Background: Cytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms.
Maira da Costa Cacemiro +11 more
doaj +1 more source
JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms
JAK2 is a tyrosine kinase gene that plays an essential role in the development of normal haematopoiesis. Hyperactivation of JAK2 occurs in myeloproliferative neoplasms by different mechanisms.
Mar Bellido, Peter A. W. te Boekhorst
doaj +1 more source
Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
Myeloproliferative neoplasms are caused by a clonal proliferation of a hematopoietic progenitor. First described in 1951 as 'Myeloproliferative Diseases' and reevaluated by the World Health Organization classification system in 2011, myeloproliferative ...
Renata Mendes de Freitas +1 more
doaj +1 more source

